Collaboration in Clinical Operations: Three Takeaways From SCOPE 2018

Posted by Qin Ye on Fri, Mar 02, 2018

Abhay Jha and Venkat Sethuraman co-wrote this blog post with Qin Ye.

More people than ever before attended the ninth-annual Summit for Clinical Ops Executives (SCOPE)—a testament to the growing importance of innovation within clinical development. Attendees from across life sciences gathered in Orlando Feb. 12-15 to discuss clinical development challenges and solutions, and to network with peers and partners.


>
Read More

How Pharma Companies Are Engaging Patients as R&D Partners

Posted by Kristyn Feldman on Wed, Nov 08, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This is the final post in a four-part series examining patient centricity within R&D.

To achieve true patient centricity in drug development, pharmaceutical companies need to follow four main principles: gain empathy for patients, uncover and meet patient needs, connect with patients and, finally, engage patients. By asking for and incorporating trial participant input at every level of R&D, the pharmaceutical industry can start to look at patients as true partners.


>
Read More

How Technology and Analytics Are Helping Big Pharma Improve Patient Engagement in R&D

Posted by Kristyn Feldman on Wed, Nov 01, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This is the third post in a four-part series examining patient centricity within R&D.

As drug development continues to grow more expensive and complex, and as patients expect to be more involved and empowered throughout the healthcare system, pharmaceutical companies are seeing the value in partnering with patients throughout the R&D process. The journey begins with building an understanding of and empathy for today’s patients, and then uncovering and meeting their needs. The third step is to hone in on how you connect with patients to increase the effectiveness of your communications.


>
Read More

How to Develop a Patient-Centric R&D Process

Posted by Kristyn Feldman on Wed, Oct 18, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This post is the first in a four-part series examining patient centricity within R&D.

The concept of patient centricity within drug development is far from novel, yet many pharmaceutical companies still struggle to put the patient at the center of their R&D efforts. In a recent article, we wrote about the need for pharmaceutical companies to become true partners in patients’ health. In fact, our research shows that engaging patients from the outset could lead to improved patient recruitment and retention and reduce R&D costs and timelines. Here’s the first step—one of four—that companies can take to start moving toward patient-centric drug development.


>
Read More

Why Pharma Manufacturers Should Partner With Rare Disease Communities

Posted by ZS Editors on Thu, Jul 06, 2017

Patient communities are a valuable asset within the life sciences industry. In the rare disease space, these groups are a vital resource for families battling disease, and serve as much-needed patient representatives to help spur funding, research and scientific advancement. ZS’s Rachael Pius weighs in on why pharmaceutical companies should view these patient communities as partners in clinical development. 


>
Read More